
Exscientia has launched Phase I trials in the US of DSP-0038 for the treatment of Alzheimer’s disease psychosis, the third …
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care

